Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 5, 2013, Pages 417-426

  Mosenzon, O ^a   Raz, I ^a   Scirica, B M ^b   Hirshberg, B ^c   Stahre, C I ^d   Steg, P G ^e   Davidson, J ^f   Ohman, P ^c   Price, D L ^c   Frederich, B ^g   Udell, J A ^b   Braunwald, E ^b   Bhatt, D L ^b,h  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Baseline characteristics; Diabetes mellitus; Trial patient

Indexed keywords

INSULIN; METFORMIN; PLACEBO; SAXAGLIPTIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; EASTERN EUROPE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH AND CENTRAL AMERICA; WESTERN EUROPE;

BASELINE CHARACTERISTICS; DIABETES MELLITUS; TRIAL PATIENT;

ADAMANTANE; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OVERWEIGHT; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84880044703     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2413     Document Type: Article

References (61)

1. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119: 1728-1735.
2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44(suppl 2): S14-S21.
3. American Diabetes Association. Diabetes statistics. Available at: http://www.diabetes.org/diabetes-basics/diabetes-statistics/
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854-868.
5. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
6. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
7. Holman RR, Paul SK, Bethel A, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
8. Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
9. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828.
10. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metabol Cardiovasc Dis 2009; 19: 604-612.
11. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
12. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
13. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
14. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613. Erratum in: Ann Intern Med 2011; 155: 67-68.
15. Evans JMM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
16. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? Diabetes Care 2008; 31: 1672-1678.
17. Food and Drug Administration: Guidance for Industry. Diabetes mellitus-evaluation cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071627.pdf
18. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. January 2010. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500073570.pdf
19. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care 2011; 34(Suppl 2): S101-S106.
20. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012; 91: 426-437.
21. Bose AK, Mocanu MM, Carr RD, Brand CC, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-151.
22. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007; 21: 253-256.
23. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975-983.
24. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293: E1289-E1295.
25. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694-699.
26. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962-965.
27. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011; 55(1-3): 10-16.
28. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and -independent pathways. Circulation 2008; 117: 2340-2350.
29. SAVOR-TIMI. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to Other Diabetes Medications (SAVOR- TIMI53). Available at: http://clinicaltrials.gov/ct2/show/NCT01107886
30. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. Am Heart J 2011; 162: 818-825.
31. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes mellitus. Postgrad Med 2010; 122: 16-27.
32. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008; 146: 243-249.
33. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005; 289: H2401-H2408.
34. Read P, Khan F, Heck P, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imag 2010; 3: 195-201.
35. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Preclinical biology and mechanism of action. Diabetes Care 2007; 30: 1335-1343.
36. Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther 2012; 136: 267-282.
37. Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010:592760.doi: 10.1155/2010/592760. Epub2010 Jun21
38. Ansorge S, Bank U, Heimburg A, et al. Recent insights into the role of dipeptidyl aminopeptidase IV (DPPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009; 47: 253-261.
39. Reinhold D, Goihl A, Wrenger S, et al. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DPP IV/CD26-knockout mice. Clin Chem Lab 2009; 47(3): 268-274.
40. Reinhold D, Bank U, Buhling F, et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology 1994; 192: 121-136.
41. Reinhold D, Vetter RW, Mnich K, et al. Dipeptidyl peptidase IV (DP IV, CD26) is involved in regulation of DNA synthesis in human keratinocytes. FEBS Lett 1998; 428: 100-104.
42. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 1999; 84: 21J-24J.
43. Raz I. Exogenous hyperinsulinemia and atherosclerosis in type 1 diabetic patients. J Diabetes Comp 2013; 27(1): 2-3. doi: 10.1016/j.jdiacomp.2012.10.003. Epub 2012 Nov 12.
44. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) Inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58(2): 157-166.
45. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124: 2338-2349.
46. Kubota Y, Miyamoto M, Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci 2012; 27(11): 1364-1370.
47. Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013 Jan 17. pii: S0021-9150(12)00879-9.
48. Johansen OE, Eubacher N, Von Eynatten M, Patel S, Woerle HJ. Cardiovascular risk with linagliptin in patients with type 2 diabetes: a pre-specified, prospective, and adjudicated meta-analysis from a large phase III program. Cardiovasc Diabetol 2012; 11: 3.
49. Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012. doi: 10.1111/j.1463-1326.2012.01565.x. [Epub ahead of print]
50. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events form a large phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12: 485-494.
51. White WB, Gorelick PB, Fleck P, Smith N, Wilson C, Pratley R. Cardiovascular events in patients receiving alogliptin: A pooled analysis of randomized clinical trials. In 70th Scientific Sessions of the American Diabetes Association: June 25-29, 2010; Orlando, Florida; 2010. Abstract 391-PP
52. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10, 246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7-10.
53. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27(Suppl 3): 57-64.
54. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metabol 2013; 15: 112-120.
55. CAROLINA: Cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. Available at: http://clinicaltrials.gov/ct2/show/NCT01243424?term=NCT01243424&rank=1
56. TECOS. Sitagliptin cardiovascular outcome study (0431-082 AM1) (TECOS). Available at: http://clinicaltrials.gov/ct2/show/NCT00790205?term=NCT00790205&rank=1
57. EXAMINE: cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00968708?term=00968708&rank=1
58. CANVAS- CANagliflozin cardiovascular Assessment Study. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01032629?term=CANVAS&rank=1
59. LEADER- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation. Available at: http://clinicaltrials.gov/ct2/show/NCT01179048?term=leader&rank=3
60. EXSCEL-Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. Available at: http://clinicaltrials.gov/ct2/show/NCT01144338?term=exenatide&rank=41
61. Choudhry NK, Avorn J, Glynn RJ, et al. Post-myocardial infarction free RX event and economic evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Eng J Med 2011; 365(22): 2088-2097.